JAZZ
Jazz Pharmaceuticals plc · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 23.86K | $4.65M | +1 | −1 |
| Q2 2026 | 135 | +4 | 47.42M | $11.41B | +7 | −4 |
| Q1 2026 | 135 | -10 | 49.63M | $8.67B | +4 | −14 |
| Q4 2025 | 144 | +2 | 48.56M | $7.62B | +2 | n/a |
| Q3 2025 | 20 | 0 | 25.68M | $3.38B | +1 | −1 |
| Q2 2025 | 17 | -1 | 21.49M | $2.28B | +1 | −2 |
| Q1 2025 | 15 | 0 | 8.34M | $1.04B | +1 | −1 |
| Q4 2024 | 15 | 0 | 8.56M | $1.05B | +1 | −1 |
| Q3 2024 | 14 | -2 | 7.38M | $822.21M | n/a | −2 |
| Q2 2024 | 16 | n/a | 7.74M | $826.28M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 23.85K | +27.9% | $4.65M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | TD Waterhouse Canada Inc. | 6 | New | $1,401 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| TD Waterhouse Canada Inc. | $1,401 | 0.0% |
Exited
| Assenagon Asset Management… | $5.10M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 568 holders, 63.82M shares, $11.28B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 2.00K sh · $472,800
Director · 6.00K sh · $1.38M
Officer · 1.20K sh · $289,128
Officer · 2.00K sh · $486,060
Director · 6.00K sh · $1.50M
Officer · 300 sh · $75,828
Officer · 18.11K sh · $4.53M
Officer · 9.26K sh · $2.33M
Officer · 11.42K sh · $2.84M
Officer · 18.19K sh · $4.51M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology